Company Profile
CellBion provides the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage.
Its portfolio also includes 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage, 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage, 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage, 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage, and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage.
It is involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis. Its portfolio also includes 225 Ac-FAP, indicated for solid tumors radiotherapy, and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. Founded in 2010, CellBion is headquartered in Seoul, South Korea.